Joan W. Miller - research works

In the progression cohort, over 2.1±1.6 years, 66/1,082 high-intensity lipophilic statin-exposed participants (6.10%) and 85/1,082 unexposed participants (7.86%) progressed to exudative AMD (sHR=0.62, 95%-CI, 0.45-0.87; P=0.006; IPCW HR=0.61, 95%-CI, 0.43-0.87; P=0.006).

Any statin use was not associated with AMD.

For cataract, the sHR was 1.18 (95%-CI, 1.03-1.34; P=0.015), and the IPCW HR was 1.20 (95%-CI, 1.05-1.38; P=0.007).

For PVD, the sHR was 1.00 (95%-CI, 0.81-1.22; P=0.96), and the IPCW HR was 1.00 (95%-CI, 0.81-1.24; P=0.99).

Time-varying analysis demonstrated that this association was strongest early in follow-up (HR ≈ 2.5 in year 1) and declined steadily, reaching non-significance (HR ≈ 1.0) by year 4.

At year 6, the cumulative incidence of nvAMD was 17.7% in the exposed cohort versus 15.2% in the nonexposed cohort.

Baseline AMD stage moderated the effect of CS, with weaker effects of CS for intermediate AMD (Interaction HR = 0.82, 95% CI, 0.78-0.92).

The rate of endophthalmitis was significantly higher for corticosteroid implants and pegcetacoplan compared to anti-VEGF injections.

The incidence of endophthalmitis was 0.097% (1 case per 1031 procedures) after vitrectomy for retinal detachment, 0.1% for trabeculectomy (1 case per 1000 procedures), 0.075% for tube shunts (1 case per 1333 procedures), and 0.068% for scleral buckle surgery (1 case per 1459 procedures).

The incidence after cataract surgery was 0.038% (1 case per 2652 procedures), 0.039% (1 case per 2551 procedures) after standalone minimally invasive glaucoma surgery, 0.02% (1 case per 5013 procedures) after goniotomy, and 0.011% for strabismus surgery (1 case per 9091 procedures).